Nilotinib Zentiva

Nilotinib, the active ingredient in Nilotinib Zentiva, is a tyrosine kinase inhibitor presented as tablets for oral use. It selectively blocks the BCR‑ABL fusion protein, a driver of leukemic cell growth, and is indicated for the treatment of chronic myeloid leukemia in adult patients, including chronic, accelerated, and blast phases.

GNH USA supplies Nilotinib Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, ensuring quality and regulatory conformity across EU and global markets through reliable logistics and dedicated customer support.

Nilotinib is a targeted therapy used in the management of chronic myeloid leukemia, a disease driven by BCR‑ABL tyrosine kinase activity.

- Chronic myeloid leukemia (chronic phase): reduces leukemic cell proliferation and improves long‑term survival. - Chronic myeloid leukemia (accelerated phase): achieves hematologic and cytogenetic responses in patients with disease progression. - Chronic myeloid leukemia (blast phase): provides disease control when combined with appropriate chemotherapy.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Rash or pruritus - Headache - Fatigue

Serious or Rare Side Effects: - QT interval prolongation and other cardiac arrhythmias - Arterial occlusive events (e.g., peripheral arterial disease) - Severe pancreatitis - Hepatic toxicity (elevated transaminases, hepatitis)

When prescribing Nilotinib, clinicians should observe several safety precautions to minimize risks.

- Cardiovascular monitoring: obtain baseline ECG and monitor QT interval regularly due to risk of prolongation. - Hepatic function: assess liver enzymes before initiation and periodically during therapy. - Electrolyte balance: correct hypokalemia, hypomagnesemia, and hypocalcemia to reduce cardiac risk. - Drug interactions: avoid concomitant use with strong CYP3A4 inhibitors and adjust doses of interacting agents. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with patient. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Nilotinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nilotinib levels and heighten adverse effects. - Proton pump inhibitors and antacids taken within 2 hours of nilotinib: reduce absorption and diminish efficacy. - Concomitant use with other BCR‑ABL inhibitors: increases risk of overlapping toxicities.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower nilotinib exposure, reducing effectiveness. - Anticoagulants such as warfarin: nilotinib can affect INR, requiring closer monitoring. - Statins metabolized by CYP3A4 (e.g., simvastatin): may increase statin concentrations, monitor for myopathy.